SUN PHARMA ADVANCED RESEARCH COMPANY
|
|
BOM : 532872     NSE : SPARC     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Good [Stock is Cheap] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Feb 07,2023 |
Price(EOD): ₹ 189.70
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Miscellaneous |
MCap: ₹ 6,155.77 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SUN PHARMA ADVANCED RESEARCH COMPANY | -1.8% | -9% | -41.9% |
SYNGENE INTERNATIONAL | -2.9% | -7.6% | -3.2% |
BLS INTERNATIONAL SERVICES | 3.1% | 10.2% | 183.1% |
LATENT VIEW ANALYTICS | -0.7% | -3% | -28.9% |
QUESS CORP | 5.7% | -4.6% | -48.6% |
DELTA CORP | -3.3% | -9.9% | -33.8% |
SECURITY AND INTELLIGENCE SERVICES INDIA | -6.1% | -9.8% | -34.5% |
JUST DIAL | 2.6% | 6.6% | -31.1% |
TEAMLEASE SERVICES | 8.9% | -0.1% | -48.4% |
FUNDAMENTAL ANALYSIS OF SUN PHARMA ADVANCED RESEARCH COMPANY
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SUN PHARMA ADVANCED RESEARCH COMPANY
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
-25.91
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -237.64 Cr
[Latest Qtr - Sep2022 - Standalone Results ] -30.32
P/B Calculated based on Book Value of Rs -203.03 Cr
[Latest Year - Mar2022 - Standalone Results ] 41.77
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2022 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA -33% -33% |
SHARE PRICE MOMENTUM OF SUN PHARMA ADVANCED RESEARCH COMPANY
SUN PHARMA ADVANCED RESEARCH COMPANY vs SENSEX
DEBT OF SUN PHARMA ADVANCED RESEARCH COMPANY
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
-0.37 -1.37 -3.59 -1.78 |
- - - - |
[Last Annual Data : Mar2022]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SUN PHARMA ADVANCED RESEARCH COMPANY
Pledged Promoter Shares |
0.9 % | |
---|---|---|
As on : Dec2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SUN PHARMA ADVANCED RESEARCH COMPANY
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
10.82% 19.95% 16.94% 16.94% |
13.17% -14.51% -24.05% -24.05% |
QtrlyTrend |
2 | |
Latest Qtr: Sep2022 | ||
Quarterly Result Analysis → |
SUN PHARMA ADVANCED RESEARCH COMPANY related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 500 | -0.3% | -3.2% | -2.4% |
S&P BSE 400 MIDSMALLCAP | -0.3% | -2.7% | -3.1% |
S&P BSE ALLCAP | -0.4% | -3.3% | -2.6% |
S&P BSE MIDSMALLCAP | -0.5% | -3.2% | -4.6% |
S&P BSE 250 SMALLCAP | -0.8% | -3% | -6.9% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 | -0.2% | -3.2% | -2.6% |
NIFTY MID SMALL400 | -0.4% | -3% | -3.2% |
NIFTY500 MULTICAP 50:25:25 | -0.4% | -3.2% | -3.5% |
NIFTY SMALLCAP250 | -1.2% | -3.5% | -9% |
You may also like the below Video Courses
FAQ about SUN PHARMA ADVANCED RESEARCH COMPANY
Is SUN PHARMA ADVANCED RESEARCH COMPANY good for long term investment?
As on Feb 07,2023, the Fundamentals of SUN PHARMA ADVANCED RESEARCH COMPANY look Poor and hence it may not be good for long term investment ! See Financial Performance of SUN PHARMA ADVANCED RESEARCH COMPANY . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SUN PHARMA ADVANCED RESEARCH COMPANY UnderValued or OverValued?
As on Feb 07,2023, SUN PHARMA ADVANCED RESEARCH COMPANY is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY ?
As on Feb 07,2023, the Intrinsic Value of SUN PHARMA ADVANCED RESEARCH COMPANY is Rs. 282.87 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -678.87
Fair Value [Median EV / Sales Model] : Rs. 282.06
Fair Value [Median Price / Sales Model] : Rs. 283.68
Estimated Median Fair Value of SUN PHARMA ADVANCED RESEARCH COMPANY : Rs. 282.87
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is SUN PHARMA ADVANCED RESEARCH COMPANY trading at a Premium or Discount?
As on Feb 07,2023, SUN PHARMA ADVANCED RESEARCH COMPANY is trading at a Discount of -33% based on the estimates of Median Intrinsic Value!